Literature DB >> 19565204

FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China.

Meilin Wang1, Dongmei Wu, Ming Tan, Weida Gong, Hengchuan Xue, Hongbin Shen, Zhengdong Zhang.   

Abstract

The FAS and FAS ligand (FASLG) system plays a key role in regulating apoptotic cell death, and corruption of this signaling pathway has been shown to participate in tumorigenesis. Functional promoter polymorphisms of the FAS and FASLG genes can alter transcriptional activities and thus alter risk of cancer. We hypothesized that the FAS -1377G>A, FAS -670A>G, and FASLG -844T>C polymorphisms in the promoter regions are associated with risk of gastric cancer. In a population-based case-control study of 332 gastric cancer cases and 324 controls, we genotyped these three polymorphisms and evaluated their association with risk of gastric cancer. We found that the FAS and FASL genotypes and the FAS haplotypes had no significant associations with risk of gastric cancer. In addition, there was no significant interaction between the FAS and FASL polymorphisms in the development of gastric cancer. The FAS and FASLG polymorphisms may not contribute to risk of gastric cancer in the southern Chinese population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565204     DOI: 10.1007/s10528-009-9264-0

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   1.890


  15 in total

1.  Association between Fas/FasL polymorphism and susceptibility to leukemia: a meta-analysis.

Authors:  Yiran Chen; Yiho He; Xiaotong Lu; Zhirui Zeng; Chen Tang; Tongyuan Xue; Yuhua Li
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Associations of three common polymorphisms in CD95 and CD95L promoter regions with gastric cancer risk.

Authors:  Fan Li; Yuliang Liu; Tao Fu; Weidong Tong; Anping Zhang
Journal:  Tumour Biol       Date:  2013-05-17

3.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

4.  The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.

Authors:  Gabriela Kniphoff da Silva Lawisch; Vanderlei Biolchi; Gabriela Kaufmann; Gabriela Nicolai; Eduarda Capitaneo; Thais Regina Rosembach; Janaina Zang; Ilma Simoni Brum; José Artur Bogo Chies
Journal:  Mol Biol Rep       Date:  2022-08-21       Impact factor: 2.742

5.  Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN.

Authors:  Seyed Amir Jalali; Fatemeh Homaei Shandiz; Jalil Tavakol Afshari; Maryam Davarpanah Tanha Ghochan; Amin Reza Nikpoor; Mojgan Mohammadi
Journal:  Rep Biochem Mol Biol       Date:  2018-10

6.  Association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer: evidence from a meta-analysis.

Authors:  Zhiming Wu; Huangen Wang; Xiufeng Chu; Jiang Chen; Shengyang Fang
Journal:  Tumour Biol       Date:  2013-05-01

7.  Lack of association between gene polymorphisms of Angiotensin converting enzyme, Nod-like receptor 1, Toll-like receptor 4, FAS/FASL and the presence of Helicobacter pylori-induced premalignant gastric lesions and gastric cancer in Caucasians.

Authors:  Juozas Kupcinskas; Thomas Wex; Jan Bornschein; Michael Selgrad; Marcis Leja; Elona Juozaityte; Gediminas Kiudelis; Laimas Jonaitis; Peter Malfertheiner
Journal:  BMC Med Genet       Date:  2011-08-24       Impact factor: 2.103

8.  CD95 rs1800682A/G variant and tumor risk in Asians: evidence from a meta-analysis of 36 case-control studies containing 22,438 samples.

Authors:  Cheng Jin; Xiaomin Wu; Yuanlong Gu; Fenglai Yuan; Qinghai Ye; Feng Dai; Lijie Zhu; Yuanyuan Mi
Journal:  Med Sci Monit       Date:  2015-02-27

9.  FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.

Authors:  Lei Xu; Xin Zhou; Feng Jiang; Man-Tang Qiu; Zhi Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 10.  FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.

Authors:  Zhou Zhong-Xing; Mi Yuan-Yuan; Ma Hai Zhen; Zou Jian-Gang; Zhang Li-Feng
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.